Table 1.

Approved Immune-Checkpoint Inhibitors Updated on March 2019 according to United States Food and Drug Administration (U.S. FDA) [6].

ICIMechanism of Action	Indication
Ipilimumab Anti-CTLA-4 antibody	• Unresectable or Metastatic Melanoma • Adjuvant Treatment of Melanoma • Advanced Renal Cell Carcinoma • Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
Pembrolizumab Anti-PD-1 antibody	• Melanoma • Non-Small Cell Lung Cancer • Small Cell Lung Cancer • Head and Neck Squamous Cell Cancer • Classical Hodgkin Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Urothelial Carcinoma • Microsatellite Instability-High Cancer	• Gastric Cancer • Esophageal Cancer • Cervical Cancer • Hepatocellular Carcinoma • Merkel Cell Carcinoma • Renal Cell Carcinoma • Endometrial Carcinoma
Nivolumab Anti-PD-1 antibody	• Unresectable or Metastatic Melanoma • Adjuvant Treatment of Melanoma • Metastatic Non-Small Cell Lung Cancer • Small Cell Lung Cancer • Advanced Renal Cell Carcinoma • Classical Hodgkin Lymphoma	• Squamous Cell Carcinoma of the Head and Neck • Urothelial Carcinoma • Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer • Hepatocellular Carcinoma.
Ipilimumab + nivolumab	• Unresectable or metastatic melanoma
Atezolizumab Anti-PD-L1 antibody	• Urothelial Carcinoma • Non-Small Cell Lung Cancer • Locally Advanced or Metastatic Triple-Negative Breast Cancer • Small Cell Lung Cancer
Avelumab Anti-PD-L1 antibody	• Metastatic Merkel Cell Carcinoma • Locally Advanced or Metastatic Urothelial Carcinoma • Advanced Renal Cell Carcinoma
Durvalumab Anti-PD-L1 antibody	• Urothelial Carcinoma • Non-Small Cell Lung Cancer
Cemiplimab Anti-PD-1 antibody	• Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) • Locally Advanced CSCC